跳至主要内容
临床试验/NL-OMON32736
NL-OMON32736已完成不适用

Randomized, double-blind, placebo-controlled study of the tolerability and pharmacokinetics of ascending single (TDU6964) and 14-day repeated (TDR6966) oral doses of SAR501788 and pilot food variability evaluation (FED6965) in healthy young male subjects - Tolerability and pharmacokinetics of 14-day repeated oral doses of SAR501788 in healthy elderly male and female subjects (TDR6967) - SAR 501788 SRD/MRD/FE/elderly study

Sanofi-aventis0 个研究点目标入组 152 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
152

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Healthy male subjects, between 18 and 45 years inclusive.
  • 2. Body weight between 50.0 and 95.0 kg inclusive, body mass index between 18.0 and 28.0 kg/m2 inclusive
  • 10. Healthy male or post-menopausal female subjects, between 60 and 75 years of age inclusive.
  • 11. Body weight between 50 kg and 105 kg if male, between 40 kg and 95 kg if female, body mass index between 18 and 33 kg/m2.

排除标准

  • Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, psychiatric, systemic, ocular or infectious disease, or signs of acute illness.
  • 2. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).

研究者

相似试验

Randomized, double-blind, placebo-controlled study... | 临床试验